News & Updates

Treatment with fuzuloparib, with or without apatinib, significantly improved progression-free survival (PFS) in patients with HER2– metastatic breast cancer (mBC) harbouring germline BRCA1/2 (gBRCA1/2) mutations compared with standard chemotherapy, according to results of a phase III study presented at ESMO 2024.

An in-home, voice-activated cognitive behavioural therapy for insomnia (CBT-I) program appears to help breast cancer survivors sleep, according to a study.

Treatment with subconjunctival triamcinolone acetonide (TA) results in a reduced risk of postoperative macular edema (ME), particularly the 10-mg/ml high-dose (4 mg) group, reports a study. Additionally, the risk of glaucoma-related events is similar to that of topical groups.

In the phase III head-to-head DELTA FORCE trial, topical delgocitinib cream gains the upper hand over oral alitretinoin – the only oral systemic therapy approved for the treatment of severe chronic hand eczema (CHE) in adults with inadequate response to topical corticosteroids.

Phototherapy, whether performed at home or in the clinic office, helps improve outcomes in plaque or guttate psoriasis, with the home-based procedure being associated with less financial burden to patients, according to a study.

Early and intensive glycaemic control continues to reduce risks of mortality, MI, and microvascular complications even at 44 years after the UKPDS study’s initiation, according to follow-up data presented at the EMW Symposium 2024.

An interim analysis of PROs from the PSORIATYK SCALP trial shows that treatment with the allosteric TYK2 inhibitor deucravacitinib significantly reduces itch, flaking, and pain specific to the scalp, as well as whole-body itch, vs placebo at week 16 in patients with moderate-to-severe scalp psoriasis, including those with less extensive BSA involvement